Chronic or heavy smoking can lead to different forms of pathologic remodeling in the airways and distal lung. There is an 8% to 19% prevalence of interstitial lung disease (ILD) in chronic smokers who were unaware that they had a lung disorder. Descriptive pathologic and radiologic analyses have enabled a number of clinical diseases to be identified and grouped within a range of smoking-related ILDs. We review the radiology, pathology, and clinical management of pulmonary Langerhans cell histiocytosis, respiratory bronchiolitisassociated ILD, and desquamative interstitial pneumonia. We discuss the difficulties of classification and also where the new entity of airspace enlargement with fibrosis fits into the current grouping. The prognosis for these conditions is variable depending on the intrinsic behavior of each condition. Smoking cessation is the first-line therapy of choice for any smoking-related ILD, whereas treatment with corticosteroids and other agents forms an important, but occasionally futile, intervention.
I n 2012, the World Health Organisation reported that 21% of the global population aged 15 years and above smoked tobacco. 1 A typical cigarette contains approximately 600 ingredients that result in approximately 7000 chemicals when burned, including many that are toxic to the respiratory system. 2 As a group, lung diseases secondary to cigarette smoking are a major cause of morbidity and mortality worldwide. Lung cancer and chronic obstructive pulmonary disease (COPD) represent headline smoking-attributed diseases, but there is evidence to also link smoking with the development of interstitial lung diseases (ILDs). As these affect a relatively smaller number of smokers compared with COPD, a complex interplay between exposure to cigarette constituents and host susceptibility factors likely underpins the pathobiology of these conditions.
In recent years, lung cancer screening trials using computed tomography (CT) of large cohorts have reported an 8% to 19% prevalence of interstitial lung abnormalities in chronic smokers who were hitherto unaware that they had a lung disorder. [3] [4] [5] Smoking may also have a role in the development of other ILDs including idiopathic pulmonary fibrosis, nonspecific interstitial pneumonia, and rheumatoid arthritis-associated ILD, as well as other connective tissue diseaseassociated ILDs. [6] [7] [8] The present review focuses on the diseases that are classically encompassed by the term "smoking-related interstitial lung disease" (SR-ILD): pulmonary Langerhans cell histiocytosis (PLCH), respiratory bronchiolitis-associated interstitial lung disease (RB-ILD), and desquamative interstitial pneumonia (DIP).
THE CLASSIFICATION CONUNDRUM
The latest American Thoracic Society/European Respiratory Society classification of idiopathic interstitial pneumonias (IIPs) (2013) retains RB-ILD and DIP as major IIPs with recognition that they fall within a broader category of smoking-related interstitial pneumonias. 9 The recently described entity of airspace enlargement with fibrosis in smokers is also discussed but is not included as a distinct form of IIP. Whether RB-ILD can truly be called idiopathic has been questioned particularly with mounting evidence that heavy or chronic smoking is a consistent factor in its development. DIP on the other hand has been described in noncigarette smokers; in many cases where the etiological trigger cannot be identified, the idiopathic label might seem reasonably applied, but it must be remembered that an inhalational agent is still responsible for the resulting pulmonary injury.
The pathologic features of >1 SR-ILD, even in limited form, may be demonstrated in the same patient including aspects of PLCH, RB-ILD, and DIP, as well as usual interstitial pneumonia, nonspecific interstitial pneumonia, and emphysema. [9] [10] [11] In patients with PLCH, pathologic and radiologic evidence of smoker's respiratory bronchiolitis (RB) and DIP are often present. [12] [13] [14] [15] The histologic and radiologic appearances of RB-ILD and DIP can also overlap. 16, 17 Other than the challenge of assigning a diagnostic label to cases where the findings do not point exclusively to 1 entity, the clinician often has to also face the task of determining whether 1 disease pattern dominates the clinical picture to specify treatment options.
A recent study investigated physiological, radiologic, and histopathologic features considered attributable to an SR-ILD in a cohort of 41 patients. The characteristics propounded in the derivation cohort were subsequently evaluated by a panel of clinicians, radiologists, and pathologists in a test cohort of 100 patients with interstitial pneumonia, only half of whom had been previous smokers. Surprisingly, the ability to discern smokers from nonsmokers in the validation cohort was found to be poor. The study demonstrated that even though specific characteristics may be attributable to the effects of smoking, the features are not reliable or specific enough to attribute a confident smoking history to a patient. Indeed, 1 of the 8 cases identified as having SR-ILD in the validation cohort had never smoked. It is also probable that the relative rarity of a SR-ILD phenotype in a population of patients with IIP may limit the assurance with which an SR-ILD diagnosis can be reached. 18 
PULMONARY LANGERHANS CELL HISTIOCYTOSIS
PLCH is a disease that is characterized by the monoclonal proliferation and abnormal infiltration of histiocytic Langerhans cells into lung tissue. Although it can form part of a multisystem syndrome, over 80% of cases occur as a single-organ disease. 12 It occurs almost exclusively in young individuals aged between 20 and 40 years with a history of cigarette smoke exposure; in 1 report, 95% of cases were either current smokers or ex-smokers. 14, 19 The actual prevalence of the disease is not known, but <5% of patients with ILD undergoing surgical lung biopsy in 1 study had PLCH. 20 In 1 Belgian study of 360 patients with different ILDs who were prospectively registered at 20 centers of respiratory medicine, PLCH was the final diagnosis in 3%. 21 The most commonly reported symptoms in patients with PLCH are dyspnea and an unproductive cough, whereas spontaneous pneumothorax forms part of the presentation in up to 15% of cases. 19, 22 The natural history of the disease is well documented, although early stages of the disease are infrequently captured on CT compared with the more established diffuse cystic pattern. 17 Plain chest radiography is insensitive for detecting PLCH but may show reticulo-micronodularity, which usually prompts cross-sectional imaging to be undertaken.
The characteristic early CT features of PLCH are of centrilobular nodules varying in size between 1 and 10 mm in diameter. The nodules typically spare the costophrenic angles and have a predilection for cavitation ( Fig. 1 ). It is the presence of cavitation that allows a distinction to be made from sarcoidosis in cases of the micronodular form of PLCH. 23, 24 Longitudinal follow-up of patients has demonstrated the evolution of cavitating nodules into thick-walled cysts, which in turn develop into thin-walled cysts. 25 Over time, cysts may coalesce, resulting in architectural distortion of the intervening lung parenchyma, a finding that may be exacerbated by fibrosis that not uncommonly supervenes in PLCH. Eventually, a destructive emphysematoid or fibrobullous appearance may manifest within the lungs, which can be impossible to distinguish from emphysema. In any case, given that the majority of patients are smokers, detailed interrogation of a CT in an attempt to distinguish emphysema from PLCH may be a futile exercise. Serial CT evaluation has also shown the regression of cysts in PLCH, 26 a finding thought to relate to the presence of active florid or cavitatory granulomas within the cyst walls.
Proving the presence of PLCH by lung biopsy has traditionally been accepted as a diagnostic requirement, but the radiologic findings on CT are often sufficiently suggestive of the disease (particularly when encountered in a young smoking patient) to obviate the need for a lung biopsy. Although less invasive, the use of bronchoalveolar lavage (BAL) to quantify the proportion of CD1a + cells in BAL fluid is not widely accepted or undertaken. Although it has been suggested that a finding of 3% CD1a + cells is suggestive of pulmonary LCH and over 5% is probably diagnostic, this dogmatic view has not received broad acceptance and probably suffers from low sensitivity. 22, 27 Transbronchial biopsy has a poor yield for diagnosing PLCH on account of the patchy nature of the disease and the small samples obtained, 28 but it may help exclude other diseases in the differential diagnoses.
Pulmonary function tests are not diagnostically specific and can be normal in up to 20% of cases. The commonest abnormality is a reduction in the diffusing capacity for carbon monoxide (DL CO ), reflecting a combination of cystic lung destruction and a degree of pulmonary vascular dysfunction, which is initially the dominant factor explaining exercise limitation early in the disease course. A restrictive abnormality is usual in the early stages of the disease, with an obstructive pattern supervening in the later stages of the disease. 22 The most important intervention in the management of PLCH is smoking cessation, and symptomatic and radiologic improvements have been reported. 29 The disease progresses in some patients despite smoking cessation, and there is as yet no reliable way to differentiate these 2 groups at the outset. 22, 30 Pharmacotherapy with corticosteroids is currently considered in patients with severe or progressive disease. The evidence for steroid effectiveness is lacking, although disease stabilization has been reported. 31 Other immunosuppressive agents, such as methotrexate, cyclophosphamide, cladribine, 32 and chlorodeoxyadenosine, 33 have also been used. It is important to consider the pulmonary vascular component, as pulmonary hypertension could supervene despite stable pulmonary parenchymal disease. Although there are no trials in this patient group, phosphodiesterase inhibitors and endothelin antagonists have been found to be of benefit. 22 Finally, lung transplantation should be considered in those with severe progressive disease despite the above therapeutic measures.
The prognosis of PLCH is variable, reflecting the wide range of clinical outcomes ranging from apparent resolution of disease to progressive worsening leading to respiratory failure. Overall, survival in PLCH is shorter than in the general population, with a median survival of 12.5 years. 19 The development of pulmonary hypertension is associated with a significantly increased mortality. 34 
RESPIRATORY BRONCHIOLITIS-ASSOCIATED INTERSTITIAL LUNG DISEASE
RB was first described in 1974 as a necropsy finding in the lungs of young asymptomatic smokers. 35 In 1987, when a small case series of 6 heavy smokers with symptomatic ILD was published, a link between RB (demonstrated at open lung biopsy) and clinically important respiratory disease was made. 36 It is now widely accepted that RB may be a pathologic and mostly subclinical finding in most, if not all, smokers, and it can occur in the absence of demonstrable airflow limitation. In a case-series analysis of 156 lung biopsy specimens, RB was present in all 83 current smokers and half of nearly 50 exsmokers. 37 The term RB-ILD has subsequently been applied to describe RB occurring in the context of clinically significant disease and to distinguish the primarily airway-centered pathologic entity from DIP, a more diffuse parenchymal lesion. 38 RB-ILD is thought to only affect current or exsmokers, but such a notion may suffer from selection bias being largely derived from case series. 36, [38] [39] [40] [41] Owing to its low reported incidence, the epidemiology of RB-ILD is not well understood. The majority of patients are young, aged between 35 and 55 years, with at least a 30 packyear smoking history. 36, [38] [39] [40] [41] [42] Some studies have reported a male preponderance, 36, 38, 40 which has not been reported by others, 39, 41 and thus a real sex predilection may not exist. 43 Unlike RB, RB-ILD is symptomatic, and the commonest presentation is one of cough and exertional dyspnea of gradual onset. Digital clubbing is rarely seen while inspiratory crackles may be auscultated in up to 50% of patients. 10 Different patterns of abnormal pulmonary function have been observed in RB-ILD, including obstructive or restrictive spirometric defects or even an isolated reduction in DL CO . 44 One common abnormality appears to be a mixed but predominantly obstructive ventilatory defect in association with moderately reduced DL CO . 45 The interpretation of pulmonary function tests may be complicated by the concomitant presence of emphysema; gross airflow obstruction in the presence of extensive emphysema will not allow the functional component attributable to RB-ILD to be delineated. Equally, a preserved (normal) forced vital capacity may be demonstrated when a combination of emphysema and interstitial fibrosis exists; in such cases, the DL CO will appear to be disproportionately, and at times profoundly, decreased. The prevalence of interstitial fibrosis in RB-ILD is variable. 41, 45, 46 Radiologically on high-resolution CT (HRCT), the features of RB-ILD are poorly defined centrilobular ground-glass nodules, areas of ground-glass opacification, bronchial wall thickening, and areas of attenuation reflecting small airways disease 17 (Fig. 2 ). There may also be limited emphysema and features of established fibrosis. There are differences across the studies in terms of the frequency of these changes and also in terms of zonal predominance. Although HRCT findings alone cannot be used to distinguish RB-ILD from RB, there does seem to be a correlation between the extent of centrilobular nodules and the amount of macrophages in respiratory bronchioles, as well as the extent of ground-glass opacification and levels of macrophage accumulation within alveoli. 47 BAL shows a characteristic increase in pigmented macrophages. A mild neutrophilia may be present, but an eosinophilia and lymphocytosis are usually absent or mild. 48 Changes in BAL cellularity do not reliably differentiate RB-ILD from DIP.
Histologically, the features of RB are not reliably distinguished from RB-ILD; both show an accumulation of alveolar macrophages with fine granular pigmentation within respiratory bronchioles and alveolar ducts, and to a lesser extent their adjacent alveoli. 11 The distinct light-brown pigmentation of these so-called "smoker's macrophages" is thought to reflect the intracellular accumulation of cigarette smoke metabolites. The degree of pigmentation has been shown to correlate with pack-years of cigarettes smoked. 37 A chronic peribronchiolar inflammatory cell infiltrate may also be evident, and, where present, histiocytes in the bronchiolar wall may contain dark anthracotic material. Finally, minimal to mild fibrosis of the bronchiolar walls is not uncommon. 10, 11 Smoking cessation and cigarette smoke avoidance together form the cornerstone of the management of RB-ILD. The evidence for this is limited, however, as findings from earlier studies showing clinical improvement after smoking cessation have not been replicated to the same extent in more recent studies. 38, 41 There is also conflicting evidence for corticosteroid use; in 1 study of 21 cases of pathologically proven RB-ILD, although the extent of bronchial wall thickening, centrilobular nodularity, and ground-glass opacification decreased with smoking cessation, signs of air-trapping (hypoattenuation) did not. 47 In a separate study of 35 cases (23 DIP and 12 RB-ILD, all biopsy-proven), corticosteroid therapy was associated with mild to modest reduction of symptoms, stabilization of lung function, and improved plain radiographic abnormalities. These observations were more common in the RB-ILD group than in those with DIP, but follow-up data did not include CT imaging. A small proportion of subjects with DIP progressed to respiratory failure and death despite smoking cessation and steroid treatment. 40 Other studies have shown similarly unimpressive responses to either intervention with respect to symptom and lung function recovery. 41 In practice, corticosteroids and conventional inhaled therapies should be considered as an adjunct to smoking cessation in patients with symptomatic or progressive RB-ILD or DIP together with an explanation of their therapeutic limitation. Similar to the situation with COPD, such patients may also benefit from a trial of pulmonary rehabilitation.
A diagnosis of RB-ILD generally carries a favorable prognosis with documented long-term survival and periods of relative stability. 41, 45 Inexorable disease progression leading to early death does not seem to describe the clinical phenotype of this disease. In a study of long-term outcome, three-quarters of patients survived >7 years after diagnosis, but many remain symptomatic to a variable extent. 41 At follow-up, just over a quarter (28%) reported symptom improvement compared with a similar proportion who did not feel better and 44% who felt worse. As a group, neither smoking cessation nor steroid treatment produced a significant positive impact on symptom outcome. 
DESQUAMATIVE INTERSTITIAL PNEUMONIA
The pathogenetic relationship between DIP and cigarette smoking is not as striking as that for RB-ILD, although there is broad consensus that DIP represents a form of SR-ILD. 9, 38, 43 In 2 case series of 20 and 26 patients, approximately 40% of subjects did not have a history of cigarette smoking. 49, 50 In a separate analysis of 62 cases with biopsy-confirmed DIP, an increased level of inorganic particles was found compared with controls; in the majority of cases, documented exposure to dust, fumes, or specific types of particles was recorded. 51, 52 Small case series and isolated reports have also implicated other potential etiological factors in DIP including mycotoxins, connective tissue diseases, rheumatoid arthritis, sirolimus, infection, and marijuana. [52] [53] [54] Similar to RB-ILD, the epidemiological data for DIP come from limited sources. DIP is usually diagnosed in patients aged between 40 and 60 years, with a reported 2-fold male predominance. 38, 40, 49, 52 The most commonly presenting symptoms are dry cough and gradual-onset exertional dyspnea. Unlike RB-ILD, a marked acute presentation of evidently progressive disease has been reported. 55 Among clinical findings, finger clubbing is present in nearly 50% of cases 38, 56 and inspiratory crackles in up to two-thirds. Pulmonary function tests typically show a restrictive ventilatory defect with impaired DL CO . 10 Radiologically, the CT appearances of DIP may be nonspecific. In a study of 23 patients with histologically proven DIP, a correct diagnosis was reached on the basis of CT alone in only 63% of cases. 57 On HRCT, the main finding is of widespread ground-glass opacification that is usually symmetrical and bilateral 17, 46, 58, 59 (Fig. 3) . Regarding distribution, a CT study of 22 cases of pathologically proven DIP identified a lower lobe and peripheral predominance in 73% and 59% of patients, respectively. 59 Peripheral cysts are not infrequently a feature of DIP, although the etiology of the cysts is not clear. Some earlier studies 46 may have confounded the cysts of DIP with honeycombing associated with usual interstitial pneumonia. 17 A more recent, smaller series of 8 patients confirmed that the cysts seen in DIP were not associated with architectural distortion and probably corresponded to dilated alveolar ducts or pulmonary cysts. 58 Patients with DIP rarely develop severe fibrosis; however, a fibrotic nonspecific interstitial pneumonitis pattern has been shown to develop on CT. 11 Nevertheless, despite the morphologic overlap between DIP and NSIP, the exact relationship between the 2 entities has yet to be elucidated. 50 BAL in DIP can disclose an increased number of leukocytes and the presence of pigmented alveolar macrophages. 52 A small rise in the fraction of eosinophils and neutrophils may also occur, but it has no specific diagnostic value. In cases in which the radiologic findings are atypical and examination of BAL does not sufficiently support or refute a diagnosis of DIP, recourse to surgical lung biopsy is inevitable.
The term "desquamative" is a misnomer and owes its adoption to the earliest descriptions of the disease, which suggested that affected alveoli were filled with desquamated or shed pneumocytes. 60 In fact, akin to the situation in RB-ILD, the pathologic hallmark is characterized by the cohesive accumulation of large numbers of macrophages with abundant brown-pigmented cytoplasm. The distribution of these cells is more diffuse than in RB-ILD, occurring throughout the pulmonary acini and accompanied by mild interstitial inflammation comprising lymphocytes and peribronchiolar lymphoid hyperplasia. Limited/mild alveolar septal fibrosis, greater in extent than in RB-ILD and not producing architectural distortion or honeycombing, is a common ancillary finding. 11 A mild eosinophilic infiltration may also be seen.
In addition to smoking cessation, patients with DIP are commonly offered treatment with corticosteroids. However, this approach is empiric and detailed evaluations are lacking. In 1 historical study, steroid treatment was associated with clinical improvement in 61.5% of patients, although deterioration was recorded in 27%. 56 Other agents with anecdotal evidence of benefit include cyclophosphamide 61 and clarithromycin. 62 As is the case for many other forms of diffuse lung disease, lung transplantation represents a final therapeutic resort. However, the co-occurrence of severe emphysema and pulmonary hypertension in DIP often precludes transplantation from being a realistic option for many patients.
A varied disease course is described in DIP, but the majority of patients with smoking-associated DIP remain relatively stable or improve to some extent with drug treatment and strict smoking avoidance. 38, 40, 56, 58, 59 The mortality rate for DIP is higher than that for RB-ILD, but it is still lower than that for usual interstitial pneumonia. In the Carrington study of 1978, a third of 40 patients monitored for a median of 9 years survived a mean of 12.2 years. 56 
SHOULD RB-ILD AND DIP REMAIN SEPARATE ENTITIES?
A major area of debate in the ILD literature concerns the positions that RB-ILD and DIP occupy within the larger group of SR-ILD and their relationship with each other. 43, 46, 48, 63 The view that the 2 diseases share a common pathobiological foundation is often advanced on the argument that both have a tendency to develop in smokers and are histologically characterized by abnormal macrophage accumulation within the respiratory bronchioles and alveolar compartment. Moreover, as elements of both RB-ILD and DIP have been described in the lungs of patients with PLCH, 15 it seems conceivable that smoking, as the common "hit," can induce different but related forms of tissue injury whose copresence in the same individual adds strength to the hypothesis. A contrary view is also held, supported by a number of observations: first, no evidence that RB-ILD can progress to DIP has yet been shown 45 ; second, the possibility that each entity may inherently progress differently exists-for example, RB-ILD may develop into a more emphysema-like disease, whereas the fibroproliferative potential of DIP may dominate and lead to a greater proportion of these patients developing frankly fibrotic lesions. The prognosis for those with RB-ILD, by comparison, is also considerably better. Finally, the therapeutic approach for managing RB-ILD is more circumspect than the more intensive strategy used in DIP.
IS "AIRSPACE ENLARGEMENT WITH FIBROSIS"
A NEW DISEASE ENTITY?
An increasing number of reports have sought to describe a "new" SR-ILD denoted by airspace enlargement with areas of focally distributed fibrosis. [64] [65] [66] Initial descriptions were pathologic and derived from the examination of lobectomy specimens from smokers with lung cancer. Confusingly, various terms have been used to describe this process, including airspace enlargement with fibrosis, 9, [66] [67] [68] smoking-related interstitial fibrosis, 64, 69 and RB with fibrosis. 65 The characteristic CT findings of the entity include subpleural cystic emphysematous spaces admixed with localized areas of reticulation. Although the distribution is predominantly within the upper lobes, the CT findings can extend to the mid-zones of the lung. 65, 68 The histologic correlate is characterized by marked alveolar septal thickening with focal hyalinized fibrosis in the subpleural and centrilobular parenchyma. Variable numbers of pigmented macrophages, emphysema, and RB may be present. 64, 65 Although the clinical implication of the diagnosis remains unclear, longitudinal follow-up has indicated that the typical disease course appears to be benign and, in some cases, nonprogressive. 70 
CONCLUSIONS
Chronic or heavy smoking can lead to different forms of pathologic remodeling in the airways and distal lung. The inhalational nature of such an injury produces bronchocentric and bronchiolocentric abnormalities that include ground-glass opacities, nodules, alveolar filling phenomena, and localized interstitial fibrosis. Descriptive pathologic and radiologic analyses have enabled a number of clinical diseases to be identified and grouped within a range of SR-ILDs. On the whole, these conditions are uncommon, and an understanding of their pathophysiological basis remains incomplete. It is likely that factors other than smoking interact in a complex manner to promote the manifestation of clinically important symptoms and physiological impairment. Patients with these conditions have a variable prognosis depending on the intrinsic behavior of each condition. Radiologic and pathologic characteristics often overlap in RB-ILD and DIP, but they differ in 1 key aspect, namely the potential for disease progression, which is considerably greater in DIP. The development of diffuse fibrosis is a crucial determinant of prognosis because of its treatment-recalcitrant nature. Smoking cessation is the firstline therapy of choice for any smoking-related ILD, whereas drug treatment with corticosteroids and other agents forms an important but occasionally futile intervention.
